TOI BUYThe Oncology Institute, Inc., a U.S.-based oncology company, reported earnings yesterday and saw a significant price gap with heavy trading volume. If the stock holds above $3 and shows follow-through tomorrow, it could be considered a buy
The Oncology Institute, Inc.
No trades
Market insights
TIO Huge potentialJust to the recent swing high is over 50%. The stock has retested to the.382 fib right now. We could see a deeper dip to the .618 but we do have a nice liquid area here at the 1.60 price range. The daily timeframe has the support of the 200ema and also has a crossover oversold stochastic. A good buy IMO
TOI | Great Entry Point | LONGThe Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services. It serves adult and senior cancer patients. The company operates 67 clinic locations. The Oncology Institute, Inc. was founded in 2007 and is based in Cerritos, California.
